Literature DB >> 10448957

Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection.

E Woolf1, I Fu, B Matuszewski.   

Abstract

A method for the determination of rofecoxib in human plasma is described. After the addition of an internal standard, buffered (pH 5) plasma samples are extracted with hexane-methylene chloride (50:50, v/v). The extracts are evaporated to dryness and reconstituted in mobile phase. Upon exposure to UV light, the analyte was found to undergo a stilbene-phenanthrene-like photocyclization reaction with the resulting formation of a highly fluorescent species. Thus, the plasma extracts were analyzed via HPLC with post-column photochemical derivatization and fluorescence detection. The assay has been validated in the concentration range of 0.5-100 ng/ml using 1-ml samples. The method has been successfully utilized to support human clinical pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448957     DOI: 10.1016/s0378-4347(99)00215-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  3 in total

Review 1.  Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

Authors:  Neal M Davies; Xiao W Teng; Neil M Skjodt
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Structural Examination of 6-Methylsulphonylphenanthro- [9,10-C]-furan-1(3H)-one-A Rofecoxib Degradation Product.

Authors:  Pamela M Dean
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-01

Review 3.  Current perspectives in NSAID-induced gastropathy.

Authors:  Mau Sinha; Lovely Gautam; Prakash Kumar Shukla; Punit Kaur; Sujata Sharma; Tej P Singh
Journal:  Mediators Inflamm       Date:  2013-03-12       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.